Macromolecular osteolytic factor synthesised by squamous carcinoma cell lines from the head and neck in vitro is interleukin 1

S. Meghji1, J.R. Sandy1, A.M. Scutt1, W. Harvey1, R.L. Carter 2 & M. Harris1

1Joint Department of Oral and Maxillofacial Surgery, Institute of Dental Surgery and University College, 256 Grays Inn Road, London WC1X 8LD and 2Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK.

Summary
Three human cell lines derived from oro-pharyngeal squamous cell carcinomas of the head were investigated for bone-resorbing activity in vitro. Culture media from all three spontaneously produced a non-dialysable osteolytic factor with activity in three in vitro assays for interleukin 1 (IL1), viz. the lymphocyte activating factor (LAF) assay, stimulation of collagenase synthesis by articular chondrocytes, and stimulation of prostaglandin E2 (PGE2) synthesis by fibroblasts. Addition of anti-human IL1 antisera to the culture media abolished all the bone-resorbing activity. Fractionation of the cell culture media by high performance liquid chromatography (HPLC) showed a single peak of activity in the chondrocyte assay with an apparent mol. wt of 15-17,000. This co-eluted with activity in a preparation of IL1 from rat peritoneal macrophage cultures. These results indicate that IL1 is responsible for the prostaglandin-independent bone resorbing activity synthesised by these cells in vitro, and may contribute to the bone destruction associated with the tumour.

Bone resorption is a common feature of malignancy and can occur as a consequence of malignant cell growth in or adjacent to bone, or at sites distant from the malignant cells. The localised bone destruction frequently accompanying squamous cell carcinomas of the head and neck appears to be a two-stage process: the first phase characterised by osteoclastic resorption – presumably stimulated by tumour cell products, and a second phase of resorption by tumour cells themselves (Carter, 1985).

Since the demonstration of soluble bone resorbing activity produced by mouse fibrosarcoma in vitro (Goldhaber, 1960), tissue culture has been an important tool for investigating the mechanisms of tumour-induced bone resorption. Prostaglandins (PG), notably PGE2, have been considered prime candidates as local mediators of osteolysis since they are potent stimulators of osteoclastic bone resorption (Klein & Raiz, 1970) and are synthesised in increased amounts by several tumours in animals, including fibrosarcomas in mice (Tashjian et al., 1972) the YX, carcinoma in rabbits (Voelkel et al., 1975), and in man, including carcinoma of the breast (Bennett et al., 1975; Dowsett et al., 1976), and squamous carcinomas of the head and neck (Tsao et al., 1981). PGs, however, are only one class of bone resorbing factor which may contribute to tumour osteolysis. Tsao et al. (1981, 1983) showed that the bone resorption induced in culture by explants of squamous cell carcinoma of the head and neck was only partially inhibited by indomethacin. Indeed, carcinoma cell lines cultured from these tumours produced bone resorbing activity in the culture supernatants, but no detectable PGs. This indicates that the PGs synthesised by tumour explants may have originated from other cell types in the tumour, such as stromal fibroblasts.

Another group of arachidonic acid metabolites, the lipoygenase products, have also been shown to possess bone resorbing activity (Meghji et al., 1987). Portered et al. (1984) demonstrated that tissue from oral squamous cell carcinoma synthesised equivalent amounts of cyclooxygenase prostaglandins and lipoygenase products.

Several macromolecular bone resorbing factors have been identified recently, including tumour transforming growth factors (TGF) (Ibbotson et al., 1983), interleukin 1 (IL1) (Gowen et al., 1983) and tumour necrosis factor (TNF) (Bertolini et al., 1986). It has become clear that IL1 and TNF account for much of the bone resorbing activity attributed to 'osteoclast activating factor' (OAF) produced by mononuclear leukocytes (Horton et al., 1972) and myeloma cells (Mundy et al., 1974). In view of the potent bone resorbing activity of IL1 and the fact that it is a normal product of keratinocytes (Luger et al., 1981), we investigated whether it contributed to the non-prostaglandin bone resorbing activity synthesised by squamous carcinoma cells in vitro.

Materials and Methods

Tumour cells
The three cell lines used were derived from squamous carcinomas of the head and neck associated with localised bone destruction, at the Institute of Cancer Research. The cell lines were established as described by Lane et al. (1981). Two of the squamous carcinoma cell lines (HN11 and 15) were derived from the floor of the mouth and the third (HN12) from the hypopharynx. For preparation of supernatant containing bone resorbing activity the cells were grown to confluence in Eagles minimal essential medium (MEM; Gibco) and 10% foetal calf serum (FCS; Gibco) in 75 cm2 polystyrene culture flasks, supplemented with penicillin, streptomycin and kanomycin (100 U ml⁻¹ each), buffered with sodium bicarbonate 2.25 g l⁻¹ in a humidified atmosphere of 95% air and 5% CO₂. The cells were subcultured weekly with 0.25% trypsin (Gibco). When the cells were confluent the medium was then replaced with serum-free MEM and incubated for a further 3 days. The medium was centrifuged at 100 g to remove any debris and 1 ml aliquots were removed for prostaglandin analysis. The remainder of the medium was stored at −20°C. Supernatants were concentrated 20 fold under pressure using Sartorius membrane filters (No. Sm 145 29-025) with a nominal molecular weight retention of 5,000. Fractionation of cell products was performed by HPLC gel permeation chromatography on a Spectra Physics with a Protein Pak 125 column (Waters, USA). The column was equilibrated with 0.15 M NaCl, 0.05 M acetic acid (pH 4) and calibrated with the following markers: bovine serum albumin (66 kD), egg albumin (45 kD), chymotrypsinogen (24.5 kD), lactoglobulin (18.4 kD), lysozyme (14.3 kD), cytochrome C (12.4 kD) and aprotinin (6.5 kD). Fractions of 250 μl were collected into sterile plastic tubes, diluted 1:40 with MEM and assayed for stimulation of collagenase synthesis in chondrocyte cultures (see below).

Mononuclear cell supernatants
Mononuclear cell factor (MCF) was obtained from cultures of adherent rat peritoneal macrophages (10⁶ ml⁻¹) stimulated with concanavalin A (10 ng ml⁻¹) for 3 days. The

Correspondence: S. Meghji.
Received 1 December 1987; and in revised form, 8 March 1988.
culture medium was dialysed against fresh medium and stored at \(-70^\circ\text{C}\).

**Bone resorption**

Bone resorption was assayed by the measurement of calcium released from 5-day old mouse calvaria in vitro (Zanelli et al., 1969). Halved calvaria were cultured singly on stainless steel grids in 30 mm dishes (5 per group), with 1.5 ml BGJ medium (Flow Laboratories, Scotland), supplemented with 5\% complement-inactivated rabbit serum and 50 \(\mu\text{g ml}^{-1}\) ascorbic acid. After 24h the media were changed, and dialysed tumour cell medium or MCF was introduced at a dilution of 1:5 to 1:40. MCF (1:10) and PGE\(_2\) (10\(^{-6}\text{M}\)) were used as positive controls. In some of the experiments polyclonal antibody for human IL1 (Genzyme, Suffolk, UK) was added to the tumour cell line media and MCF and incubated overnight at 4\(^{\circ}\text{C}\) before testing for bone resorbing activity. The cultures were incubated for a further 48h and the calcium content of the media was measured by automated colorimetric analysis (Gitelman, 1967). In order to ascertain the potency of the tumour cell media recombinant human IL1 beta was tested on the bone resorbing system in parallel.

**Thymocyte proliferation assay**

Interleukin 1-like activity was measured by its capacity to enhance the mitogen-stimulated proliferation of mouse thymocytes (the "lymphocyte activation factor" (LAF) assay, Ged-da et al., 1972). Briefly, thymocytes from 7-week old C3H-HeJ mice (Harlan Olac, Blackthorn, UK) were plated in 96 well culture plates (Sterilin) at 1.5 \(\times 10^5\) per well in 100 \(\mu\text{l}\) RPMI 1640 containing 5\% complement-inactivated FCS, 4 \(\mu\text{M}\) 2-mercaptoethanol, and 0.5 \(\mu\text{g ml}^{-1}\) concanavalin A. The cultures were incubated for 48h and 3H-thymidine (Amer- sham International), 0.5 \(\mu\text{Ci per well}, was added for the last 6h. Incorporation of 3H-thymidine into 5\% trichloroacetic acid-insoluble material was measured by scintillation counting.

**Chondrocyte collagenase assay**

Rabbit articular chondrocytes were prepared by a method adapted from Evequez et al. (1984). Slices of articular cartilage from the knee and shoulder joints of 2-week old New Zealand white rabbits were sequentially digested with 0.5\% hyaluronidase (Sigma) for 20 min at 37\(^{\circ}\text{C}\), followed by 0.25\% trypsin and 0.1\% bacterial collagenase (Sigma) for 1h at 37\(^{\circ}\text{C}\) in serum free MEM, then 0.1\% bacterial collagenase for 2h in the presence of 10\% FCS.

The cells obtained were washed twice and grown to confluence in MEM with 10\% FCS. Cell suspensions from the cultures were prepared by trypsin digestion (0.25\%), and inoculated into 16 mm wells in 24-well culture plates at 200,000 cells per well. The culture medium was removed when the cells were confluent, and 0.5ml aliquots test preparations diluted in MEM incubated in triplicate wells for 48h.

The supernatants were assayed for collagenase activity using thermally reconstituted 3H-acetylated rat skin collagen fibrils (Cawston & Barrett, 1979). Latent collagenase in triplicate 50 \(\mu\text{l}\) samples of the supernatants was activated with 20 \(\mu\text{l}\) of 10\% 4-amino phenyl mercuric acetate (Sigma) and incubated with collagen fibrils (10,000 dpm/tube) for 5h at 37\(^{\circ}\text{C}\). Collagenase activity was calculated from the release of radioactivity into the solution, and expressed as Uml\(^{-1}\) where 1 U digests 1 \(\mu\text{g}\) of collagen per minute.

**Tumour necrosis factor assay**

The bioassay for TNF activity is based on cytotoxicity to the murine connective tissue cell line L929 (Flick & Gifford, 1984). Cytotoxicity was measured by the quantitative uptake of methylene blue stain by the cells after fixation (Currie, 1981).

L929 cells were seeded into 96-well microtitre plates (Sterilin) at 4 \(\times 10^4\) cells per well. After overnight attachment, the medium was removed and replaced with fresh serum-free MEM containing actinomycin D (1 \(\mu\text{g ml}^{-1}\)) and serial dilutions of the standard human recombinant TNF alpha (Genzyme, Suffolk, UK) and tumour cell media at dilution from 1:1 to 1:256 in MEM. After a 24h incubation the medium was discarded and the cells were fixed with 5\% normal formal-saline and stained with methylene blue. The stain was eluted into 100 \(\mu\text{l}\) 0.1\% HCl, and the absorbance was measured at 650 nm on an automated multi-channel spectrophotometer (Titertek Multiscan, Flow Laboratories, Scotland).

**Stimulation of fibroblast PGE\(_2\) synthesis**

Fibroblast cultures were established from normal gingival tissue obtained during routine oral surgery, and grown to confluence in MEM with 10\% FCS. The medium was changed twice weekly, until primary cultures were established. The fibroblasts were subcultured weekly by trypsinisation (0.25\%), and used between the 4th and 8th passage. Fibroblasts were seeded in 16 mm culture wells (Sterilin) at 50,000 cells per well. The test preparations were diluted in MEM and 0.5 ml aliquots incubated with the cells for 48h. PGE\(_2\), in the culture media was measured by radioimmunoassay: 3H-PGE\(_2\) was obtained from Amersham International; PGE\(_2\) antiserum from Steranti and PGE\(_2\) standards from Sigma.

**Results**

**Bone resorption**

The supernatants from all three cell lines caused significant bone resorption, comparable with that produced by MCF. This was partially inhibited by the addition of indomethacin (Figure 1a).

The concentration-dependence of resorbing activity in the tumour cell media is shown in Figure 1b and of recombinant IL1 in Figure 1c. Addition of anti-IL1 to the tumour cell line media and MCF completely inhibited their osteolytic activity (Figure 1d).

**Thymocyte proliferation**

The tumour cell culture media enhanced the proliferation of Con A-induced mouse thymocytes, indicating the production of IL-1 like activity (Figure 2). The stimulation produced was similar to that obtained by the preparation of MCF.

**Chondrocyte collagenase production**

All three cell lines stimulated collagenase production by rabbit articular chondrocytes in culture (Figure 3). None of the tumour cell-conditioned media had collagenase activity.

**L929 cytotoxicity assay for TNF**

The concentration of TNF that gave 50\% maximal cell killing (1 U) was equivalent to 150 pg ml\(^{-1}\) of recombinant human TNF alpha. There was no detectable TNF activity in any of the tumour cell culture media in any of the concentration tested (results not shown).

**Fibroblast PGE\(_2\) synthesis**

All three tumour cell media contained negligible PGE\(_2\) (<0.1ng ml\(^{-1}\)) but enhanced PGE\(_2\) synthesis on addition to fibroblasts. The stimulation was comparable to that obtained with the MCF preparation (Figure 4).

**HPLC**

The HPLC fractions were assayed for IL1 activity in chondrocyte collagenase assay. The results (Figure 5) showed a single major peak of stimulator activity which co-eluted with that in the MCF preparation at an Mr of 15-17,000.
Figure 1 (a) The effects of cell supernatant (diluted 1:10) (with and without indomethacin (10^-6 M) on bone resorption. Crossed hatched bars show the effect of indomethacin. Mononuclear cell factor (MCF) and PGA_2 (10^-6 M) were used as positive controls. The results are shown as mean ± s.d. (n=5 bones per group). *P<0.001 compared with the control group. (b) The effects of conditioned media from the cell lines (diluted 1:40, 1:20, 1:10 and 1:5) PGA_2 (10^-6 M) was used as positive control. The results are shown as mean ± s.d. (n=5 bones per group). *P<0.05 compared with the control group. HN11 - X-; HN12 - O-; HN15 — -. (c) The effect human recombinant IL1 at the following concentrations; 0.01, 0.1, 1 and 10 nM on bone resorption. PGA_2 (10^-6 M) was used as positive control. The results are shown as mean ± s.d. (n=5 bones per group). *P<0.05 compared with the control group. (d) The effects of tumour cell culture media and MCF (diluted 1:10) on bone resorption and the effect of the same media in the presence of anti-human IL1 on bone resorption (crossed hatched bars) PGA_2 (10^-6 M) was used as positive control. The results are shown as mean ± s.d. (n=5 bones per group). *P<0.001 compared with the control group. The bone resorbing activity of MCF and the three cell lines was abolished by the addition of anti-human IL1.

Discussion

These results have demonstrated that squamous carcinoma cell lines synthesize an osteolytic factor in vitro with the characteristics of the cytokine IL1. These, and similar cell lines which have previously been validated in terms of their karyotypes, ultrastructure and growth as xenografts, are known to synthesise osteolytic activity which was not attributable to prostaglandin E_2, and was largely unaffected.
Fractionation of the culture media by HPLC (Figure 5) showed that the stimulatory activity in the chondrocyte collagenase assay co-eluted with MCF at an Mr of 15-17,000. This is also consistent with its identity as IL1 (Dinarello et al., 1977).

Recently another cytokine, TNF, has also been shown to share several characteristics of IL1 (reviewed by Le & Vilee, 1987) including the stimulation of bone resorption in vitro (Bertolini et al., 1986). As the mol. wt of TNF (17,000) is similar to that of IL1 it is possible that TNF contributed to the stimulation of bone resorption and PGE2 synthesis by fibroblasts. However, no TNF-like activity was detectable in the tumour cell media over a wide range of dilutions. Furthermore TNF does not exhibit activity in the LAF assay (Dinarello et al., 1985) and does not stimulate metabolism of prostaglandins by chondrocytes (Schnyder et al., 1987). TNF does not, therefore appear to contribute to the osteolytic activity synthesised by the tumour cells in vitro.

Another family of peptides, tumour-derived transforming growth factors (TGF), have recently been shown to stimulate bone resorption (Tashjian et al., 1985; Ibbotson et al., 1986) and are thought to be potential mediators of tumour-induced osteolysis. However, TGF does not show IL1-like activity in the LAF and chondrocyte collagenase assays, and is therefore unlikely to contribute to the activity which co-elutes with IL1 on HPLC.

The initial stages of tumour-induced bone destruction are mediated by osteoclastic activity, whereas the later stages can involve direct invasion and destruction of the bone by tumour cells alone (Galasko & Bennett, 1976; Carter, 1985). There is much evidence that prostaglandins are synthesised by human carcinomas (Bennett et al., 1975; Dowsett et al., 1976; Tsao et al., 1981, 1983) and, in view of their potent bone resorbing activity, notably PGE2 (Klein & Raisz, 1970), they have been considered prime candidates as osteolytic mediators. The experiments reported by Tsao et al. (1983) showed that although explanted tumour fragments synthesised amounts of PGE2 enough to account for the majority of bone resorption in vitro, the carcinoma cell lines synthesised little prostaglandins but significant prostaglandin-independent osteolytic factors. The experiments reported here show that IL1 may account for this PG-independent osteolytic activity.

Although IL1 is an extremely potent resorbing peptide and may contribute to osteolysis by the tumour tissue, its ability to stimulate prostaglandin synthesis in connective tissue cells may be of equal or greater importance. Fibroblasts are target cells for IL1 action and respond by synthesising prostaglandins – notably PGE2 (Dayer et al., 1977; Mizel et al., 1981), PGF2 and prostacyclin (Harvey et al., 1984). In the squamous cell carcinoma, therefore, secretion of IL1 by the carcinoma cells is likely to stimulate prostaglandin synthesis by the infiltrating stromal cells such as fibroblasts and capillary endothelial cells.

We propose, therefore that IL1 secretion by the carcinoma cells can cause bone resorption by two mechanisms: stimulation of osteoclast activity, probably mediated by osteoblasts (Thomson et al., 1986), and indirectly by the stimulation of prostaglandin synthesis in stromal cells infiltrating or surrounding the tumour.

References

BENNETT, A., MCDONALD, A.M., SIMPSON, T.S. & STAMFORD, I. (1975). Breast cancer, prostaglandins and bone metastases, Lancet, i, 1218.

BERTOLINI, D.R., NEDWIN, G.E., BRINGMAN, T.S., SMITH, D.D. & MUNDAY, G.R. (1986). Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature, 319, 516.

CARTER, R.L. (1985). Patterns and mechanisms of localised bone invasion by tumours: studied with squamous cell carcinoma of the head and neck. CRC Critical Rev. Clin. Lab. Sci., 22, 275.

CAWSTON, T.E. & BARRETT, A.J. (1979). A rapid and reproducible assay for collagenase using [1,14C] acetylated collagen. Analyst. Biochem., 99, 340.

CURRIE, G.A. (1981). Platelet-derived growth factor requirements of in vitro proliferation of normal and mesenchymal cell. Br. J. Cancer, 43, 335.

DAYER, J.M., ROBINSON, D.R. & KRANE, S.M. (1977). Prostaglandin production by rheumatoid synovial cells: Stimulation by a factor from human mononuclear cells. J. Exp. Med., 145, 1399.
MACROMOLECULAR OSTEOLYTIC FACTOR

DINARELLO, C.A., RENFER, L. & WOLFF, S.M. (1977). Human leukocytic pyrogen purification and development of a radioimmunoassay. Proc. Natl Acad. Sci. USA, 74, 4624.

DINARELLO, C.A. (1985). An update on human interleukin-1 from molecular biology to clinical relevance. J. Clin. Immunol., 5, 287.

DOWSETT, M., EASTY, G.C., POWLES, T.J., EASTY, D.M. & NEVILLE, A.M. (1976). Human breast tumour-induced osteolysis and prostaglandins. Prostaglandins, 11, 447.

EVEQUOZ, V., BETTEN, F., KRISTENSEN, F. & 5 others (1984). Interleukin 2-independent stimulation of rabbit chondrocyte and prostaglandin E2 production by and interleukin 1-like factor. Eur. J. Path., 14, 490.

FLICK, D.A. & GIFFORD, G.E. (1984). Comparison of in vitro cell cytotoxic assay for tumour necrosis factor. J. Immunol. Methods, 78, 167.

GALASKO, C.S.B. & BENNETT, A. (1976). Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature, 263, 508.

GERY, I., GERSHON, R.K. & WAKSMAN, H. (1967). Potentiation of the T-lymphocyte response to mitogen. I. The responding cells. J. Exp. Med., 136, 128.

GITTELME, S.M., NG, M.K.B. & RUSSEL, R.K. (1984). Evidence for fibroblasts as the major source of prostacyclin and prostaglandin synthesis in man. Arch. Oral Biol., 29, 223.

HARVEY, W., FOO, G.-C., GORDON, D., MEGHJI, S., EVANS A. & HARRIS, M. (1984). Evidence for fibroblasts as the major source of prostacyclin and prostaglandin synthesis in man. Arch. Oral Biol., 29, 223.

HORTON, J.E., RAISZ, L.G., SIMMONS, H.A., OPPOHME, J.J. & MERGENHAGEN, S.E. (1972). Bone resorbing activity in supernatant fluid from human cultured peripheral blood leukocytes. Science, 177, 793.

IBBOTSON, K.J., D’SOUSA, S.M., NG, K.W. & 4 others (1983). Tumour-derived growth factor increases bone resorption in tumour associated with humoral hypercalcaemia of malignancy. Science, 221, 1292.

IBBOTSON, K.J., HARROD, J., GOWEN, M. & 5 others (1986). Human recombinant transforming growth factor a stimulates bone resorption and inhibits formation in vitro. Proc. Natl Acad. Sci., USA, 83, 2228.

KLEIN, D.C. & RAISZ, L.G. (1970). Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology, 86, 1436.

LE, J. & VILCEK, J. (1987). Biology of diseases. Tumour necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab. Invest., 56, 234.

LUGER, T.A., STADLER, B.M., KATZ, S.I. & OPPENHEIM, J.J. (1981). Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J. Immunol., 127, 1493.

MEGHJI, S., SCOTT, A. & HARVEY, W. (1987). Stimulation of bone resorption by lipoygenase products in vitro. J. Dent. Res., 66, 233.

MIZEL, S.B., DAYER, J.M., KRANE, S.M. & MERGENHAGEN, S.E. (1981). Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte activity factor (interleukin 1). Proc. Natl Acad. Sci. USA, 78, 2474.

MUNDY, G.R., RAISZ, L.G., COOPER, R.A., SCHECHTER, G.P. & SALMON, S.E. (1974). Evidence for the secretion of an osteoclast stimulation factor from myeloma. J. Exp. Med., 140, 1041.

PORTER, H., MATEJKA, M., ULRICH, W. & SINZINGER, D. (1984). The cyclo-oxygenase and lipoygenase pathway in human oral cancer tissue. J. Maxillo. Surg., 12, 145.

SCHMIDTER, J., PAYNE, T. & DINARELLO, C.A. (1987). Human monocyte and recombinant interleukin 1’s are specific for the secretion of metalloproteinases from chondrocytes. J. Immunol., 138, 496.

TASHIJA, A.H., VOELKEL, E.T., LEVINE, L. & GOLDBHABER, P. (1972). Evidence that bone-resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E2; a new model for the hypercalcaemia of cancer. J. Exp. Med., 136, 1329.

TASHIJA, A.H., VOELKEL, E.F., LAZZARO, M. & 5 others (1985). Alpha and beta human transforming growth factors stimulation prostaglandin production and bone resorption in cultured mouse calvaria. Proc. Natl Acad. Sci., USA, 82, 4535.

THOMSON, B.M., SAKLATVALA, J. & CHAMBERS, T.J. (1986). Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. J. Exp. Med., 164, 104.

TSAO, S.W., BURMAN, J.F., EASTY, D.M., EASTY, G.C. & CARTER, R.L. (1981). Some mechanisms of local bone destruction by squamous cell carcinoma of head and neck. Br. J. Cancer, 43, 392.

TSAO, M., BURMAN, J.F., PITTMAN, M.R. & CARTER, R.L. (1983). Further mechanisms of bone destruction by squamous cell carcinoma of the head and neck: The role of host stroma. Br. J. Cancer, 48, 497.

VOELKEL, E.F., TASHIJA, A.H., FRANKLIN, R. et al. (1975). Hypercalcaemia and tumour-prostaglandins. The VX2 carcinoma model in the rabbit. Metabolism, 24, 973.

ZANELLI, I.M., LEA, D.J. & NISBET, J.A. (1969). A biosassay method in vitro for parathyroid hormone. J. Endocrinol., 43, 36.